Hepatic hemangioma is the most common benign tumor in the liver, with a significantly higher incidence in women than men (3:1) and an average age of onset of 45 years. Capillary hemangiomas are usually less than 5 cm in diameter and occur equally in the left and right hepatic lobes, while hepatic giant hemangiomas are hemangiomas larger than 5 cm in diameter. Hemangiomas are difficult to distinguish from malignant tumors of the liver when coagulation or coiled structures occur within the hepatic hemangioma. Usually, hepatic vessels do not cause symptoms, and most of them are detected during imaging. When clinical symptoms appear, it is still necessary to exclude other diseases that may be underlying, because in half of the patients, clinical symptoms are not caused by hepatic hemangioma. The natural course of hepatic hemangiomas is a benign one, and no malignant changes have been reported in hepatic hemangiomas, which usually remain stable for many years, with few complications such as rupture and bleeding. Complications such as rupture and bleeding rarely occur. Patients with asymptomatic hepatic hemangiomas usually do not require treatment, but only clinical observation. Surgical treatment is also required when hemangiomas rupture, bleed, grow rapidly, and develop Kasabach-Merritt syndrome. Hepatic hemangiomas account for 12% of liver tumors in children, and they can affect other organs by presenting multiple foci.